JPS6468400A - Human tumor cytotoxic factor htcf, production thereof and antitumor agent comprising said factor as active ingredient - Google Patents

Human tumor cytotoxic factor htcf, production thereof and antitumor agent comprising said factor as active ingredient

Info

Publication number
JPS6468400A
JPS6468400A JP62224065A JP22406587A JPS6468400A JP S6468400 A JPS6468400 A JP S6468400A JP 62224065 A JP62224065 A JP 62224065A JP 22406587 A JP22406587 A JP 22406587A JP S6468400 A JPS6468400 A JP S6468400A
Authority
JP
Japan
Prior art keywords
htcf
factor
human tumor
antitumor agent
tumor cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62224065A
Other languages
Japanese (ja)
Inventor
Saburo Sone
Masanobu Munakata
Makoto Tanaka
Akito Nakamura
Terukazu Uchida
Minoru Kamimura
Yoshitada Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapporo Breweries Ltd
Original Assignee
Sapporo Breweries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapporo Breweries Ltd filed Critical Sapporo Breweries Ltd
Priority to JP62224065A priority Critical patent/JPS6468400A/en
Publication of JPS6468400A publication Critical patent/JPS6468400A/en
Pending legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NEW MATERIAL:Human tumor cytotoxic factor hTCF having 30,000+ or -5,000mol. wt. and pH 6.0+ or -0.5 isoelectric point. USE:An antitumor agent. PREPARATION:For example, peripheral blood of healthy people is collected, a mononuclear cell is isolated by centrifugal separation, inoculated into a medium containing bovine fetal serum and lipopolysaccharide, cultivated at 37 deg.C for 16hr, the mononuclear cell is removed by centrifugal separation and the culture mixture is filtered by a membrane filter and sterilized to give crude hTCF-containing solution. The solution is concentrated by an ultrafilter, passed through a column packed with crosslinked dextran gel, eluted to collect a fraction having cytocidal effects. The fraction is concentrated and purified by high- performance liquid gel filtration chromatography to give hTCF.
JP62224065A 1987-09-09 1987-09-09 Human tumor cytotoxic factor htcf, production thereof and antitumor agent comprising said factor as active ingredient Pending JPS6468400A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62224065A JPS6468400A (en) 1987-09-09 1987-09-09 Human tumor cytotoxic factor htcf, production thereof and antitumor agent comprising said factor as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62224065A JPS6468400A (en) 1987-09-09 1987-09-09 Human tumor cytotoxic factor htcf, production thereof and antitumor agent comprising said factor as active ingredient

Publications (1)

Publication Number Publication Date
JPS6468400A true JPS6468400A (en) 1989-03-14

Family

ID=16808018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62224065A Pending JPS6468400A (en) 1987-09-09 1987-09-09 Human tumor cytotoxic factor htcf, production thereof and antitumor agent comprising said factor as active ingredient

Country Status (1)

Country Link
JP (1) JPS6468400A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043665A1 (en) * 1997-03-28 1998-10-08 Snow Brand Milk Products Co., Ltd. Preventive and/or therapeutic agent for kidney diseases
US7115568B2 (en) 1997-03-14 2006-10-03 Daiichi Pharmaceutical Co., Ltd. Methods using TCF II

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115568B2 (en) 1997-03-14 2006-10-03 Daiichi Pharmaceutical Co., Ltd. Methods using TCF II
WO1998043665A1 (en) * 1997-03-28 1998-10-08 Snow Brand Milk Products Co., Ltd. Preventive and/or therapeutic agent for kidney diseases
US6306827B1 (en) 1997-03-28 2001-10-23 Snow Brand Milk Products Co., Ltd. Method for preventing and/or treating renal disease

Similar Documents

Publication Publication Date Title
Roth Jr et al. Glucose-6-phosphate dehydrogenase deficiency inhibits in vitro growth of Plasmodium falciparum.
GB8819590D0 (en) Flow/return of blood cells to patient/donor after centrifugal separation
IE41057L (en) Refining lipid compositions.¹¹semi-permeable membrane to separate, e.g. phosphol-lipids
BE904368A (en) NOVEL PYRIDYLMETHOXY- AND METHYLMERCAPTOANILINE DERIVATIVES USEFUL IN PARTICULAR AS ANTIASTHMATICS, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THEM.
CA2006658A1 (en) An anticoagulant substance obtained from urine
Tsuboi et al. Two Forms of Glucoamylase from Mucor rouxianus 1. Purification and Crystallization
ATE43244T1 (en) PHARMACEUTICAL COMPOSITION IN OINTMENT FORM FOR DERMIC AND OPHTHALMIC USE.
AU678343B2 (en) Method and composition for determining the immunological activity of bioactive substances
US4129648A (en) Method for reducing endogenous prostaglandin synthesis
Fojo et al. The isolation and characterization of a colony stimulating factor from human lung
FR2603587A1 (en) 2,3,4,5,6,7-HEXAHYDRO-2,7-METHANO-1,5-BENZOXAZONINE (OR -1,4-BENZOXAZONINE) DERIVATIVES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM AND INTERMEDIATE COMPOUNDS
BG96324A (en) PHARMACOLOGY ACTIVE SUBSTANCE VRS, METHOD OF ITS OBTAINMENT AND ITS THERAPEUTIC APPLICATION
US5000953A (en) Biologically active substance
FR2548671B1 (en) PROCESS FOR THE PREPARATION OF A GLOBIN FROM HEMOGLOBIN AND A GLOBIN OBTAINED BY THIS PROCESS
EP0516845A4 (en) Novel megakaryocytic colony stimulating factor and process for its preparation.
US5008371A (en) Biologically active polypeptide and use thereof
ATE4216T1 (en) 3-HYDROCARBYLTHIO-2-ACYLOXYPROPYL 2TRIMETHYLAMMONIOETHYL PHOSPHATE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
EP0134247A1 (en) Protein with oncostatic effect, process for its preparation, and oncostatic drug containing it
GB2144332A (en) Pharmaceutical preparations containing fructose-1,6-diphosphate
GB1495940A (en) Anti-cancer active whey fraction
KR100233873B1 (en) Vasodilation composition containing lumbrokinase
Coeugniet et al. Lymphocyte Membrane Modifications induced by Acetylsalicylic Acid and Dipyridamole
Badmajew Jr et al. PADMA-28: An immunoregulatory substance in vitro
Schindler et al. Stimulatory effects of MOP and its butyl ester derivative on macrophage proliferation and activation in vitro
SU1162435A1 (en) Method of treatment of staphilococcal sepsis